http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111494351-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111494351-B |
| titleOfInvention | Application of basic fuchsin in antitumor and medicine |
| abstract | The invention discloses an application of basic fuchsin in tumor resistance and a medicine, and relates to the technical field of tumor treatment. The invention discloses an application of basic fuchsin in preparation of an anti-tumor medicament, wherein the tumor is a tumor with positive EGFR expression. The research of the invention discovers for the first time that the basic fuchsin can obviously improve the life quality of a patient with advanced lung adenocarcinoma, prolong the life cycle, inhibit the proliferation of human lung adenocarcinoma cells, reduce the mRNA expression of PI3K, Akt and mTOR, weaken the protein expression of p-PI3K, p-Akt and p-mTOR, and prompt that the basic fuchsin can be used for treating tumors such as tumors with positive EGFR expression. The invention provides a new treatment method, a new strategy and a new idea for preventing and treating tumors with positive EGFR expression, in particular tumors with drug resistance after being treated by an epidermal growth factor receptor tyrosine kinase inhibitor. |
| priorityDate | 2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.